FULC

Fulcrum Therapeutics, Inc. · NASDAQ · Healthcare · USD · 10-K for 2025, filed 2026-02-24

Figures on this page computed 2026-11-08 12:40 UTC

Last close

3.77USD

Market data, 2026-11-04

Except where said otherwise: 10-K for 2025, filed 2026-02-24

n/aP/E
We do not hold this figure for this company, so there is nothing to place.
Price / Earnings per Share (diluted)
Source
computed
Fiscal year
2025
Accession
0001193125-26-065197
Reported in
USD
- computed
- 10-K for 2025, filed 2026-02-24
The filing itself
n/aROIC
We do not hold this figure for this company, so there is nothing to place.
NOPAT / Invested Capital x 100, where NOPAT = Operating Income x (1 - Tax Rate) and Invested Capital = Equity + Total Debt - Cash
Source
computed
Fiscal year
2025
Accession
0001193125-26-065197
Reported in
USD
- 10-K for 2025, filed 2026-02-24
- 10-K for 2025, filed 2026-02-24
- 10-K for 2025, filed 2026-02-24
- 10-Q for 2025, filed 2026-07-30
- 10-K for 2025, filed 2026-02-24
- 10-Q for 2025, filed 2026-07-30
The filing itself
n/aNet margin
We do not hold this figure for this company, so there is nothing to place.
Net Income / Revenue x 100
Source
computed
Fiscal year
2025
Accession
0001193125-26-065197
Reported in
USD
- 10-K for 2025, filed 2026-02-24
- 10-K for 2025, filed 2026-02-24
The filing itself
n/aFCF margin
We do not hold this figure for this company, so there is nothing to place.
Free Cash Flow / Revenue x 100
Source
computed
Fiscal year
2025
Accession
0001193125-26-065197
Reported in
USD
- 10-K for 2025, filed 2026-02-24
- 10-K for 2025, filed 2026-02-24
The filing itself
n/aDebt/equity
We do not hold this figure for this company, so there is nothing to place.
Total Debt / Shareholders' Equity
Source
computed
Fiscal year
2025
Accession
0001193125-26-065197
Reported in
USD
- 10-K for 2025, filed 2026-02-24
- 10-Q for 2025, filed 2026-07-30
The filing itself
n/aDividend yield
We do not hold this figure for this company, so there is nothing to place.
Source
computed
Taken on
2026-11-07
Reported in
USD
- computed

Growth is the furthest below its sector's middle: 0.02 against 0.50 on the market's range.

Margins: n/aWe do not hold this figure for this company, so there is nothing to place.
What it pays out: n/aWe do not hold this figure for this company, so there is nothing to place.

Five bars, one line

lens 7 of 9

0.00x

1.16x

1.13x

n/a

0.41x

SalesProfitFree cash flowDebtPrice

Each bar against this company's own average; the line is that average.

Filed2025

Market data2026-11-04

Each against its own average

4 of 5 read

Except where said otherwise: 10-K for 2025, filed 2026-02-24

Sales0.00x
Its own average over 6 years, 19.5M.
Profit1.16x
Its own average over 9 years, -64.6M.
Free cash flow1.13x
Its own average over 9 years, -53.6M.
Debtn/a
Its own average over 1 year, 34.6M.
Price0.41x
Its own average over 8 years, 9. Market data, 2026-11-04

Sales is furthest from its own average, at 0.00 times.

Sales is 0.00 times its own 6-year average; Profit is 1.16 times its own 9-year average; Free cash flow is 1.13 times its own 9-year average; Price is 0.41 times its own 8-year average.

Every figure in this lens

Except where said otherwise: 10-K for 2025, filed 2026-02-24

Sales against its own 6-year average0.00
Source
filed
Statement
income
Fiscal year
2025
Accession
0001193125-26-065197
Reported in
USD
The filing itself
Profit against its own 9-year average1.16
Source
filed
Statement
income
Fiscal year
2025
Accession
0001193125-26-065197
Reported in
USD
The filing itself
Free cash flow against its own 9-year average1.13
Source
filed
Statement
income
Fiscal year
2025
Accession
0001193125-26-065197
Reported in
USD
The filing itself
Debt against its own 1-year averagen/a
Not held.
Source
filed
Statement
income
Fiscal year
2025
Accession
0001193125-26-065197
Reported in
USD
The filing itself
Price against its own 8-year average0.41Market data, 2026-11-04
Source
market
Taken on
2026-11-04
Reported in
USD